<DOC>
	<DOC>NCT00334802</DOC>
	<brief_summary>To investigate efficacy, safety and PK of gemcitabine and paclitaxel combination in patients with metastatic breast cancer after adjuvant/neo-adjuvant chemotherapy with anthracycline regimen</brief_summary>
	<brief_title>Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically and/or cytologically confirmed breast cancer Received adjuvant/neoadjuvant chemotherapy for breast cancer with anthracycline regimen To have at least one measurable region Eastern Cooperative Oncology Group (ECOG) Performance Status: 01 To have adequate organ function (bone marrow, liver and renal function) To have interstitial pneumonia or pulmonary fibrosis To have inflammatory breast cancer Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery To have brain metastases with symptoms To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>